Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · June 30, 2024

Outcomes of Treatment-Resistant Neovascular AMD Switched From Aflibercept to Faricimab Therapy

Ophthalmology Retina

 

Additional Info

Ophthalmology Retina
Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab
Ophthalmol Retina 2024 Jun 01;8(6)537-544, R Raimondi, T Falfeli, A Bogdanova-Bennet, D Varma, M Habib, A Kotagiri, DH Steel, M Grinton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading